Table 1.
Sociodemographic, clinical, and treatment response data from background population controls, as well as patients with MDD at baseline and week 8 follow-up.
| Variable | Controls, full (N = 856) | Controls, matched (N = 67) | Baseline (n = 100) | Week 8 (n = 82) |
|---|---|---|---|---|
| Sex (F (%) / M (%)) | 511 (59.7) / 345 (40.3) | 50 (74.6) / 17 (25.4) | 73 (73.0) / 27 (27.0)* | |
| Age (years) | 38.4 (4.6) | 28.5 (2.4) | 27.0 (8.1)* | |
| Smokers (N (%)) | 131 (15%) | 9 (13.4) | 19 (19%) | |
| BMI (kg/m2) | 24.5 (4.7) | 22.9 (4.4) | 24.6 (5.6)# | |
| Mean glucose (mmol/L) | 5.8 (0.5) | 5.7 (0.4) | 5.6 (0.9)* | |
| Plasma creatinine (µM) | 74.1 (14.5) | 74.8 (16.3) | 71.8 (13.2) | |
| Plasma escitalopram (nM) (n = 71) | 78.3 (45.3) | |||
| Plasma duloxetine (nM) (n = 7) | 139.6 (82.0) | |||
| HAM-D6 | 12.3 (1.6) | 5.9 (3.8)** | ||
| HAM-D17 | 22.9 (3.4) | 11.5 (6.6)** | ||
| Treatment response (N (%)) | ||||
| Non-responders | 14 (17.3) | |||
| Intermediate responders | 44 (54.3) | |||
| Remitters | 23 (28.4) |
Signifcant differences between the groups are marked with * (full control population) and # (fully age- and sex-matched control population) vs. patients at baseline, or ** (patients at baseline vs. week 8). Data were analyzed with independent samples t-tests, paired samples t-tests or chi-squared tests, as appropriate. Data are presented as means (standard deviation) if not otherwise stated.